Ultrasound Shown to be Superior Diagnostic Compared to Mammography in Women Ages 30-39
Ramucirumab Improves Overall Survival, Progression-Free Survival in Phase III Trial
New Phase III Follow-Up Data of Yervoy Trial Shows 19 Percent Survival at Four Years
Two Phase II Trials Display Ramucirumab Potential Efficacy
Gene Variant Associated With 44 Percent Cancer Risk Reduction
Five-Fold Increase in Chordoma Risk Linked to Common Gene Variant
HCT Survivors More Likely To Show Heart Disease Risk Factors
PV-10 Produces 51 Percent Response Rate in Phase II Trial
Folic Acid, Vitamins B6 and 12 Do Not Affect Colorectal Adenoma Risk
Three Studies Test Oncotype DX In Breast and Colon Cancers
NCI-Approved CTEP Trials For the Month of October
FDA Approves Abraxane And Alimta for NSCLC
Trending Stories
- A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- RFK Jr. floats the idea of barring government scientists from publishing in leading medical journals due to “corruption”
- George Sigounas named the first-ever chief science advisor at NCI
- The other side of the patient portal: Reflections from a cancer center leader
- Surviving cancer is often not a patient’s most challenging battle
